UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
| (Address of registrant’s principal executive office) | (Zip code) |
(
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
The purpose of this amendment to the Current Report on Form 8-K/A (the “Form 8-K/A”) filed by Dicerna Pharmaceuticals, Inc. (the “Company”) with the Securities and Exchange Commission on August 6, 2020 (the “Form 8-K”), is to add Inline eXtensible Business Reporting Language (“iXBRL”) tagging to the cover page of this Form 8-K/A and to furnish Exhibit 104 to this Form 8-K/A relating to the same that was inadvertently omitted from the original Form 8-K.
| Item 2.02 | Results of Operations and Financial Condition. |
On August 6, 2020, Dicerna Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial and operational results for the quarter ended June 30, 2020. A copy of the press release is furnished herewith as Exhibit 99.1.
| Item 7.01 | Regulation FD Disclosure. |
The Company previously announced that it would host its virtual research and development day event (the “R&D Day”) on August 6, 2020 from 10:00 a.m. to 12:00 p.m. Eastern time. On August 6, 2020, the Company issued a press release related to its R&D Day, a copy of which is furnished herewith as Exhibit 99.2. In addition, the Company is posting to the “Investors” portion of its website at http://investors.dicerna.com/ a copy of its slide presentation to be used at the R&D Day. This slide presentation is attached to this Current Report on Form 8-K as Exhibit 99.3.
The information in Items 2.02 and 7.01 of this Form 8-K (including Exhibits 99.1, 99.2 and 99.3 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
| Item 8.01 | Other Events. |
On August 5, 2020, the Company announced that Shreeram Aradhye, M.D. was appointed to serve as the Company’s Chief Medical Officer, effective as of September 8, 2020. In connection with such appointment, the Company issued a press release on August 5, 2020, a copy of which is attached as Exhibit 99.4 to this Current Report on Form 8-K.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
| Exhibit No. |
Description | |
| 99.1 | Press Release, entitled “DicernaTM Announces Second Quarter Ended June 30, 2020 Financial Results and Provides Corporate Updates.” | |
| 99.2 | Press Release, entitled “Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria, and Presents Preclinical Data Applying RNAi Technology in New Tissues.” | |
| 99.3 | Dicerna 2020 Virtual R&D Update: Nedosiran, RG6346 and Going Beyond GalXCTM presentation. | |
| 99.4 | Press Release, entitled “Dicerna Announces Appointment of Shreeram Aradhye, M.D., as Executive Vice President and Chief Medical Officer.” | |
| 104 | Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 11, 2020 | DICERNA PHARMACEUTICALS, INC. | |||||
| By: | /s/ Douglas M. Fambrough, III | |||||
| Douglas M. Fambrough, III, Ph.D. | ||||||
| Chief Executive Officer | ||||||